CN1899297A - Schefflera venulosa extract and use in producing medicine - Google Patents
Schefflera venulosa extract and use in producing medicine Download PDFInfo
- Publication number
- CN1899297A CN1899297A CN 200610011036 CN200610011036A CN1899297A CN 1899297 A CN1899297 A CN 1899297A CN 200610011036 CN200610011036 CN 200610011036 CN 200610011036 A CN200610011036 A CN 200610011036A CN 1899297 A CN1899297 A CN 1899297A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extract
- effective part
- quercetin
- part extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 241001136717 Schefflera venulosa Species 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 51
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 27
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 19
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 19
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 14
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 14
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000005875 quercetin Nutrition 0.000 claims abstract description 14
- 229960001285 quercetin Drugs 0.000 claims abstract description 14
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 230000004089 microcirculation Effects 0.000 claims abstract description 8
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 150000007513 acids Chemical class 0.000 claims abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 8
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 8
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 8
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 8
- 229940074393 chlorogenic acid Drugs 0.000 claims description 8
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 8
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 8
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 8
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 7
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 7
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 7
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 7
- 235000005493 rutin Nutrition 0.000 claims description 7
- 229960004555 rutoside Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 claims description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 2
- 240000005385 Jasminum sambac Species 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 229930182470 glycoside Natural products 0.000 abstract description 3
- -1 quercetin glycoside Chemical class 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000012360 testing method Methods 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- 239000013558 reference substance Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001529246 Platymiscium Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000955 prescription drug Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000203383 Schefflera Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000203379 Schefflera arboricola Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is schefflera venulosa extract and its preparation process and use in preparing medicine. The schefflera venulosa extract contains mainly caffeoyl acids 5-40 wt%, quercetin glycoside 15-55 wt% and oleanolic acid glycoside 15-45 wt%. The schefflera venulosa extract may be prepared into orally taken preparation or injection alone or together with pharmaceutically acceptable supplementary material, and the medicine preparation may be used in promoting blood circulation to disperse blood clots, improving microcirculation, and preventing and treating acute myocardial ischemia, coronary heart disease, angina pectoris and other cardiac and cerebral vascular diseases.
Description
Technical field
The present invention relates to the effective part extract of a kind of plant, and the preparation method of described effective part extract and the purposes in pharmaceutical field.
Background technology
Schefflera venulosa (Wight et Arn.) Harms Schefflera venulosa Wight et Arn. is a kind of Araliaceae schefflera platymiscium.Evergreen dungarunga, high 5-7 rice, palmately compound leaf, lobule 5-7 sheet, ellipse, long 5-10 centimetre, wide 2.5-4 centimetre, the short gradually point of tip, base portion is circular to little heart, full edge, the long 2-4 of petiolule centimetre.Panicle is about 15 centimetres; Floral white, fragrance, bennet is obvious.The berry sphere, mulberry when ripe.Record in " Yunnan drug standard version in 1974 ".Have alleviating pain and detumescence, the effect of relaxing muscles and tendons and activating QI and blood in the collateral is used for rheumatic ostalgia, headache.Be distributed in middle part, Yunnan, the west and south, the southeast, south and the northwestward, Guizhou, western part, Hunan etc.In 37 kinds of state-owned schefflera platymisciums, Chang Zuowei is medicinal have ten surplus kind.This platymiscium major part do not carry out chemical constitution study or study not enough system, effective ingredient is also indeterminate.Comprise 2 pharmacopeia kinds (recording) and 2 ministry standard kinds with Radix Schefflerae Arboricolae as the prescribed preparation of prescription drug in version pharmacopeia in 1977, comprise 6 ministry standard kinds with Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) (S.arboricola) as the prescribed preparation of prescription drug, comprise 4 ministry standard kinds with Cortex schefflerae octophyllae as the prescribed preparation of prescription drug, all be used for expelling wind and removing dampness, soothing the channels and quicking the network vessels, physique enhancing and bone strengthening, reducing swelling and alleviating pain.The existing pharmaceutical preparation that belongs to other kind together is mainly the preparation of crude extract preparation, and chemical constitution study is system not, and the composition that plays curative effect is also indeterminate.
Summary of the invention
Purpose of the present invention promptly is to provide a kind of definite ingredients, quality controllable, medicinal extract and preparation safely and effectively by the research to Schefflera venulosa (Wight et Arn.) Harms (Schefflera venulosa Wight etArn.), and the new purposes of this extract in pharmacy is provided.
Invention thinking of the present invention based on: in further investigation Schefflera venulosa (Wight et Arn.) Harms chemical constituent and active component process, finding to contain caffeoyl acids, Quercetin glycocide, oleanolic acid glycocide in the Schefflera venulosa (Wight et Arn.) Harms, is its important activity composition.Therefore, provide a kind of effective part extract of definite ingredients, it is characterized in that this extract active component contains the caffeoyl acids that 5-40% is mainly chlorogenic acid, isochlorogenic acid C, jasmine element; 15-55% is mainly rutin, Quercetin-7-O-glc, Quercetin-3-O-glc, the Quercetin glycocide of Quercetin-3-O-glc (6-1) xly, Quercetin-3-O-glcUA, 15-45% oleanolic acid glycocide.The chemical constitution sketch map is seen accompanying drawing 1.Accompanying drawing 2 is HPLC collection of illustrative plates of extract of the present invention, has reflected the chemical composition overview of this extract intuitively.
Effective part extract of the present invention can prepare by following technical solution:
Process route is got the Herb of Schefflera venulosa (Wight et Arn.) Harms or root, stem, leaf as shown in Figure 3, pulverizes, extract 2-4 time with 0-95% ethanol water or aqueous acetone solution, merge extractive liquid,, concentrating under reduced pressure, concentrated solution add sour adjust pH to 3-5, last macroporous adsorption resin chromatography, elder generation's water eluting, reuse 55-70% ethanol elution is collected the 55-70% ethanol elution, decompression and solvent recovery, residue dried are promptly.
A key character of present technique is to use macroporous adsorption resin chromatography to carry out the refining of crude extract, to remove impurity such as desaccharide, protein, aminoacid, has improved the content of active component.
This extract has remarkable difference with the existing pharmaceutical preparation that belongs to other kind together, and the existing pharmaceutical preparation that belongs to other kind together is mainly the preparation of crude extract preparation, and chemical constitution study is system not, and effective ingredient is also indeterminate.Extract effective ingredient of the present invention is comprehensive, and chemical composition is clear, and quality controllable, has drug effect and wider indication group preferably.
The invention provides the content assaying method of effective part extract, use HPLC method control caffeoyl acids main component chlorogenic acid contents, the content of Quercetin glycocide hydrolyzate Quercetin and the content of oleanolic acid glycocide hydrolyzate oleanolic acid; UV method control Quercetin glycocide and oleanolic acid glycocide content, content assaying method is as follows:
The chlorogenic acid high effective liquid chromatography for measuring.
Strong to close silica gel be filler to the test of chromatographic condition and system suitability with octadecylsilane; With fine-0.4% phosphoric acid solution (13: 87) of second is mobile phase; The detection wavelength is 327nm.Theoretical cam curve must not calculate by the chlorogenic acid peak and is lower than 2500.
The preparation precision of reference substance solution takes by weighing through 24 hours chlorogenic acid reference substance of phosphorus pentoxide drying under reduced pressure, adds methanol and makes the solution that every 1ml contains chlorogenic acid 0.04mg, in contrast product solution.
The preparation precision of need testing solution takes by weighing this product 5mg in the 25ml volumetric flask, adds methanol and is diluted to scale, shakes up, and filters with microporous filter membrane (0.45 μ m), gets filtrate, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, and calculate chlorogenic acid contents.
The Quercetin high effective liquid chromatography for measuring.
Strong to close silica gel be filler to the test of chromatographic condition and system suitability with octadecylsilane; With fine-0.4% phosphoric acid solution (36: 64) of second is mobile phase; The detection wavelength is 254nm.Theoretical cam curve must not calculate by the Quercetin peak and is lower than 2500.
The preparation precision of reference substance solution takes by weighing through 24 hours Quercetin reference substance of phosphorus pentoxide drying under reduced pressure, adds methanol and makes the solution that every 1ml contains Quercetin 0.03mg, in contrast product solution.
The preparation precision of need testing solution takes by weighing this product 150mg, add methanol 20ml, 25% hydrochloric acid 5ml, shake up, put in the water-bath reflux 30 minutes, be cooled to room temperature rapidly, be transferred in the 50ml measuring bottle, be diluted to scale with methanol, shake up, filter with microporous filter membrane (0.45 μ m), get filtrate, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, and calculate the content of Quercetin.
The oleanolic acid high effective liquid chromatography for measuring.
Strong to close silica gel be filler to the test of chromatographic condition and system suitability with octadecylsilane; With second eyeball-water (84: 16) is mobile phase; The detection wavelength is 203nm.Theoretical cam curve must not calculate by the oleanolic acid peak and is lower than 2500.
The preparation precision of reference substance solution takes by weighing through 24 hours oleanolic acid reference substance of phosphorus pentoxide drying under reduced pressure, adds methanol and makes the solution that every 1ml contains oleanolic acid 0.1mg, in contrast product solution.
The preparation precision of need testing solution takes by weighing this product 100mg, adds 10% sulfuric acid solution 60ml, puts in the water-bath reflux 4 hours, takes out, and puts coldly, filters, and residue washes with water to neutrality, and in 60 ℃ of oven dry.The accurate chloroform 50ml that adds claims to decide the weight supersound extraction and takes out after 30 minutes and put coldly, supplies original weight with chloroform, and precision is measured test liquid 25ml evaporate to dryness, residue adds dissolve with methanol, moves in the 5ml measuring bottle, adds methanol to scale and shakes up, filter with microporous filter membrane (0.45 μ m), get filtrate, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, and calculate the content of oleanolic acid.
Quercetin glycocide spectrophotometry.
The control substance of Rutin formulations prepared from solutions: precision takes by weighing through 24 hours control substance of Rutin of phosphorus pentoxide drying under reduced pressure, adds methanol and makes the solution that every 1ml contains rutin 0.2mg, in contrast product solution.
The standard curve preparation: accurate rutin contrast liquid 0,0.5,1.0,1.5,2.0, the 2.5ml of drawing, put respectively in the 25ml measuring bottle, add 5% sodium nitrite test solution 1.0ml, shake up the back and place 6min, add 10% aluminum nitrate solution 1.0ml and shake up, place 6min, add 4%NaOH liquid 10ml, jolting adds water to scale, shake up the back and place 15min, with first bottle as blank, in the interscan of 360-650nm scope, determine the optimum detection wavelength, measure each mark product trap at this wavelength place, get regression equation.
Sample determination: precision takes by weighing the about 10mg of sample in the 10ml volumetric flask, add 90% dissolve with methanol and be diluted to scale, the above-mentioned solution 1ml of accurate absorption, put in the 25ml measuring bottle, by operating under the standard curve drafting item, measure trap, obtain the concentration that is equivalent to rutin contrast liquid from regression equation, and obtain the content of Quercetin glycocide total in each test sample according to trap.
Oleanolic acid glycocide spectrophotometry.
The preparation of oleanolic acid reference substance solution: precision takes by weighing through 24 hours oleanolic acid reference substance of phosphorus pentoxide drying under reduced pressure, adds methanol and makes the solution that every 1ml contains oleanolic acid 0.4mg, in contrast product solution.
The standard curve preparation: accurate oleanolic acid contrast liquid 0,10,20,30,40, the 60ml of drawing, put respectively in the tool plug test tube, volatilize, add 5% vanillin-glacial acetic acid liquid 0.2ml, perchloric acid 0.8ml jumps a queue and shakes up, and heats 20min in 70 ℃ of water-baths, take out, be cooled to room temperature after, add ethyl acetate to 5ml, shake up, with first bottle as blank, in the interscan of 400-650nm scope, determine the optimum detection wavelength, measure each mark product trap at this wavelength place, get regression equation.
Sample determination: precision takes by weighing the about 10mg of sample in the 10ml volumetric flask, add dissolve with methanol and be diluted to scale, the above-mentioned solution 20 μ l of accurate absorption, by operating under the standard curve drafting item, measure trap, obtain the concentration that is equivalent to oleanolic acid contrast liquid according to trap from regression equation, and obtain the content of oleanolic acid glycocide total in each test sample.
The present invention relates to the Schefflera venulosa (Wight et Arn.) Harms effective part extract as the application in the medicine of preparation microcirculation improvement.
The present invention relates to the Schefflera venulosa (Wight et Arn.) Harms effective part extract as the application in the medicine of the anti-acute myocardial ischemia of preparation.
The present invention relates to the application in the Schefflera venulosa (Wight et Arn.) Harms effective part extract is used for the treatment of coronary heart disease, angina pectoris, myocardial infarction, apoplexy sequela as preparation the medicine.
The present invention relates to the application in the Schefflera venulosa (Wight et Arn.) Harms effective part extract is used for the treatment of acute and chronic cerebral ischemia, cerebral infarction, cerebral thrombosis as preparation the medicine.
The invention has the advantages that:
1, the invention provides the effective part extract that the plant Schefflera venulosa (Wight et Arn.) Harms can be used as drug component, this extract can use separately, also can mix use with the other plant extract.
2, the present invention has excavated new medical application to the known plants Schefflera venulosa (Wight et Arn.) Harms, has opened up a new application.
3, Schefflera venulosa (Wight et Arn.) Harms effective part extract safety non-toxic of the present invention, pharmacological action is strong, is indicating well prospect in medicine.
4, the medicine that is mixed with of Schefflera venulosa (Wight et Arn.) Harms effective part extract of the present invention can be used as multiple dosage form, as: oral capsule, tablet, drop pill, granule, oral liquid, soft capsule, injection etc.
In order to understand essence of the present invention better, will its new purposes in pharmacy be described with the pharmacological testing and the result of Schefflera venulosa (Wight et Arn.) Harms effective part extract below.
One, toxicity test
The result shows
The Schefflera venulosa (Wight et Arn.) Harms effective part extract is to the LD of ICR mice through filling stomach approach acute toxicity
50Be 19.48 ± 2.73g/kg, 95% the credible 16.94～22.40g/kg that is limited to.
Two, anticoagulant effect test
Investigate the Schefflera venulosa (Wight et Arn.) Harms effective part extract to the maximum accumulative inhibitory action of platelet with the isolated rabbit platelet aggregation test.The result shows that the Schefflera venulosa (Wight et Arn.) Harms effective part extract all produces the inhibitory action of concentration dependency to platelet aggregation.
Three, Mice Auricle microcirculation test
Observe the Schefflera venulosa (Wight et Arn.) Harms extract by normal microcirculation of Mice Auricle and the experimental model of microcirculation obstacle of adrenalin hydrochloride induced mice the Mice Auricle microcirculation is had or not influence.The result shows that the Schefflera venulosa (Wight et Arn.) Harms effective part extract has the effect of obvious microcirculation improvement.
Four, Acute Myocardial Ischemia in Rats effect test
The acute myocardial ischemia model that adopts rat branch of coronary artery ligation method to cause, the function of resisting myocardial ischemia of observation Schefflera venulosa (Wight et Arn.) Harms effective part extract.After the result showed the ligation of rat branch of coronary artery, II led ECG ST section and obviously raises, and presented tangible ischemia injury performance, and the ST section significantly reduces behind the oral Schefflera venulosa (Wight et Arn.) Harms effective part extract of rat; The ligation of rat branch of coronary artery is after 24 hours, and serum AST, LDH, CK-MB all significantly raise, and behind the oral Schefflera venulosa (Wight et Arn.) Harms effective part extract of rat LDH, CK-MB level are significantly reduced; The ligation of rat branch of coronary artery is after 24 hours, and tangible ischemic necrosis lesion region appears in cardiac muscular tissue, and its infarcted region volume is about 129.8mm
3, account for 86.4% of hazardous area volume, account for 34.5% of left chamber cumulative volume.Behind the close arteries and veins goose palm of the rat orally give effective site bavin extract, infarcted region/hazardous area percent by volume, the long-pending percentage ratio of infarcted region/left chamber body are significantly descended.
Five, to the influence of rat cerebral ischemia model due to the middle cerebral artery blocking-up (MCAO)
Use FeCl
3Cause focal cerebral ischemia in rats, give the high, medium and low dosage of the oral Schefflera venulosa (Wight et Arn.) Harms effective part extract of rat model, every day 1 time, continuous 5 days, can obviously improve the rat behavior obstacle, dwindle the cerebral infarction scope.
Six, to the influence of anesthetized dog cerebral blood flow
The anesthetized dog duodenum gives the Schefflera venulosa (Wight et Arn.) Harms effective part extract high, medium and low dosage, reduces the vertebral artery resistance but the result is a dose dependent, the expansion vertebral artery.The also obvious cerebral blood flow increasing amount of high dose.
Seven, to the hemodynamic influence of anesthetized open-chest dog
Anesthetized open-chest dog gives the Schefflera venulosa (Wight et Arn.) Harms effective part extract high, medium and low dosage, and every hemodynamic index is not had obvious influence; Can bring high blood pressure down, total peripheral resistance and arteria coronaria resistance, increase cardiac pumping function, other hemodynamic parameter is not had obvious influence.
Eight, to the influence of high blood viscosity rat blood viscosity
The high, medium and low dosage of rat orally give Schefflera venulosa (Wight et Arn.) Harms effective part extract, every day 1 time, continuous 5 days, can obviously reduce the whole blood viscosity of the high viscosity mass formed by blood stasis rat that macromolecule right rotary glycoside causes, may suppress relevant with erythrocyte aggregation.
Description of drawings
Accompanying drawing 1 is the structure chart of 8 chemical constituents of Schefflera venulosa (Wight et Arn.) Harms of the present invention
Accompanying drawing 2 is the HPLC collection of illustrative plates and the main component of extract of the present invention
Accompanying drawing 3 is the technological process of feedstock production extract of the present invention with the Schefflera venulosa (Wight et Arn.) Harms for the present invention
With embodiment more specifically the preparation method of effective part extract of the present invention and preparation thereof is illustrated below.
Embodiment 1: the extract preparation
Get dry Herb 1000 grams of Schefflera venulosa (Wight et Arn.) Harms, be ground into coarse powder, add 10 times of amount 75% alcohol reflux three times, 3 hours for the first time, 2 hours for the second time, 2 hours for the third time, filter, behind the filtrate recycling ethanol, add sour adjust pH to 3-5, cross macroporous adsorptive resins, first water eluting, reuse 55-70% ethanol elution, get pure eluting part, concentrate drying is pulverized, and promptly gets the yellowish-brown powdered extract.
Embodiment 2: preparation tablets
Get extract 100g of the present invention, starch 80g, dextrin 5g mix homogeneously, add 10% starch slurry system soft material, granulate with the online of 14 order nylon, 60-70 ℃ of aeration-drying, 16 mesh sieve granulate add magnesium stearate 1.5g, carboxymethyl starch sodium 5g mixing, be pressed into 1000, coating promptly.Every contains extract 100mg.Become human oral every day 2-5 time, at every turn the 1-10 sheet.
Embodiment 3: the capsule preparation
Get extract 100g of the present invention, add starch 78g, magnesium stearate 2g mixing, directly be filled to 1000 with Autocapsulefillingmachine, polishing promptly.Every contains extract 100mg.Become human oral every day 2-5 time, at every turn the 1-10 grain.
Embodiment 4: the drop pill preparation
Get extract 12g of the present invention, drop in the polyethylene glycol 6000 of 32g heating and melting, be stirred to dissolving, be transferred in the reservoir, airtight and insulation is regulated drop pill machine drop quantitative valve at 80-90 ℃, splash into from top to bottom in 10-15 ℃ the liquid Paraffin, make 1000 altogether, the drop pill that forms is drained and wipe liquid Paraffin, be drying to obtain.Every contains extract 12mg.Become human oral every day 2-5 time, at every turn the 10-80 grain.
Embodiment 5: the oral liquid preparation
Get extract 20g of the present invention, be mixed and heated to 85-90 ℃ with Mel 300g, sucrose 50g, sodium benzoate 2g and distilled water 300ml, stir and make dissolving, insulation 30min filters, and the filtrate thin up stirs evenly to 1000ml, embedding (every 10ml), and sterilization is promptly.Become human oral every day 2-5 time, 1-5 props up at every turn.
Embodiment 6: the granule preparation
It is an amount of to get 1 part of extract of the present invention, 2 parts in dextrin, 10 parts of cane sugar powders and ethanol, and mixing is crossed 10 mesh sieves and made granule, in 60-70 ℃ of drying, and granulate, packing is promptly.The heavy 5g of every bag.Become human oral every day 2-5 time, each 1-5 wraps.
Embodiment 7: the injection preparation
Get extract 100g of the present invention, add the injection water and make dissolving in right amount, 0.02% activated carbon that adds amount of preparation stirs 5-10min, filter, filtrate is diluted to about 10L, adds sodium chloride adjusting osmotic pressure and oozes to waiting, transfer pH7.5-8.0, ultrafiltration, embedding become 1000 (10ml/ props up), and 100 ℃ of 30min sterilizations promptly.Adult's vein or administered intramuscular, every day 1-2 time, each 1-5 props up.
Embodiment 8: the injectable powder preparation
Get extract 100g of the present invention, add injection water and dilute sodium hydroxide and make dissolving in right amount, 0.02% activated carbon that adds amount of preparation stirs 5-10min, filters, and the filtrate thin up is transferred pH6.5-7.8 to the 1L, ultrafiltration, and spray drying, dry powder is promptly aseptic subpackaged.Every 100mg faces with before adding the injection water and makes dissolving in right amount, with the slowly intravenous drip of sodium chloride transfusion 250-500ml dilution back.Adult every day 1-2 time, 1-5 props up at every turn.
Embodiment 9: the freeze-dried powder preparation
Get extract 100g of the present invention under the aseptic condition, in sterile chamber, add the injection water to about 950ml, stir and make dissolving, transfer pH6.5-7.5, add the injection water to 1000ml, 0.02% activated carbon that adds amount of preparation then stirs 5-10min, filters with aseptic suction funnel, reuse sterilization sintered filter funnel fine straining or ultrafiltration, filtrate is sub-packed in the 2ml ampoule after the assay was approved, frozen drying, and aseptic sealing by fusing is promptly.Every 100mg faces with before adding the injection water and makes dissolving in right amount, with the slowly intravenous drip of sodium chloride transfusion 250-500ml dilution back.Adult every day 1-2 time, 1-5 props up at every turn.
Claims (10)
1, a kind of Schefflera venulosa (Wight et Arn.) Harms effective part extract is characterized in that this extract active component contains the caffeoyl acids that 5-40% is mainly chlorogenic acid, isochlorogenic acid C, jasmine element; 15-55% is mainly rutin, Quercetin-7-O-glc, Quercetin-3-O-glc, the Quercetin glycocide of Quercetin-3-O-glc (6-1) xly, Quercetin-3-O-glcUA, 15-45% oleanolic acid glycocide.
2,, it is characterized in that preparation method is to get the Herb of Schefflera venulosa (Wight et Arn.) Harms or root, stem, leaf, pulverizes according to the described effective part extract of claim 1, extract 2-4 time with 0-95% ethanol water or aqueous acetone solution, merge extractive liquid,, concentrating under reduced pressure, concentrated solution add sour adjust pH to 3-5, last macroporous adsorption resin chromatography, elder generation's water eluting, reuse 55-70% ethanol elution is collected the 55-70% ethanol elution, decompression and solvent recovery, residue dried are promptly.
3, the described effective part extract of claim 1 is as the application in the medicine of preparation microcirculation improvement.
4, the described effective part extract of claim 1 is as the application in the medicine of the anti-acute myocardial ischemia of preparation.
5, the described effective part extract of claim 1 is used for the treatment of the application in the medicine of coronary heart disease, angina pectoris, myocardial infarction, apoplexy sequela as preparation.
6, the described effective part extract of claim 1 is used for the treatment of the application in the medicine of acute and chronic cerebral ischemia, cerebral infarction, cerebral thrombosis as preparation.
7, contain the preparation that right requires 1 effective part extract and available support or excipient.
3, according to the preparation of claim 7, wherein said preparation is tablet or capsule or drop pill or granule or oral liquid.
9, according to the preparation of claim 7, wherein said preparation is an injection.
10, according to the preparation of claim 9, wherein said preparation is powder pin and liquid drugs injection form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610011036 CN1899297A (en) | 2006-07-11 | 2006-07-11 | Schefflera venulosa extract and use in producing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610011036 CN1899297A (en) | 2006-07-11 | 2006-07-11 | Schefflera venulosa extract and use in producing medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1899297A true CN1899297A (en) | 2007-01-24 |
Family
ID=37655407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610011036 Pending CN1899297A (en) | 2006-07-11 | 2006-07-11 | Schefflera venulosa extract and use in producing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1899297A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969547A (en) * | 2018-08-09 | 2018-12-11 | 云南省药物研究所 | Application of the Radix Schefflerae Arboricolae extract in the drug that preparation prevents and treats cardiovascular and cerebrovascular |
| FR3068893A1 (en) * | 2017-07-17 | 2019-01-18 | Caster | TULIP EXTRACT |
| CN112591746A (en) * | 2020-12-14 | 2021-04-02 | 广东省农业科学院作物研究所 | Tobacco stem-based activated carbon electrode material self-doped with sulfur element and preparation method and application thereof |
| CN112891330A (en) * | 2021-03-15 | 2021-06-04 | 云南民族大学 | Application of aspartame in preparation of anti-migraine drug |
| CN113230260A (en) * | 2021-05-19 | 2021-08-10 | 复旦大学附属华山医院 | Method for constructing animal disease model of persistent gouty arthritis |
| CN114177146A (en) * | 2022-01-17 | 2022-03-15 | 南宁市第一人民医院 | Preparation and content determination method of schefflera octophylla formula particles |
| CN115590845A (en) * | 2022-11-15 | 2023-01-13 | 中国科学院遗传与发育生物学研究所（Cn） | Application of isochlorogenic acid C in the treatment of myocardial injury caused by antineoplastic drugs |
| CN116693585A (en) * | 2023-06-08 | 2023-09-05 | 大洲新燕(厦门)生物科技有限公司 | Method for preparing quercetin-7-O-beta-D-glucoside from dried orange peel and application thereof |
-
2006
- 2006-07-11 CN CN 200610011036 patent/CN1899297A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3068893A1 (en) * | 2017-07-17 | 2019-01-18 | Caster | TULIP EXTRACT |
| CN108969547A (en) * | 2018-08-09 | 2018-12-11 | 云南省药物研究所 | Application of the Radix Schefflerae Arboricolae extract in the drug that preparation prevents and treats cardiovascular and cerebrovascular |
| CN112591746A (en) * | 2020-12-14 | 2021-04-02 | 广东省农业科学院作物研究所 | Tobacco stem-based activated carbon electrode material self-doped with sulfur element and preparation method and application thereof |
| CN112891330A (en) * | 2021-03-15 | 2021-06-04 | 云南民族大学 | Application of aspartame in preparation of anti-migraine drug |
| CN113230260A (en) * | 2021-05-19 | 2021-08-10 | 复旦大学附属华山医院 | Method for constructing animal disease model of persistent gouty arthritis |
| CN114177146A (en) * | 2022-01-17 | 2022-03-15 | 南宁市第一人民医院 | Preparation and content determination method of schefflera octophylla formula particles |
| CN115590845A (en) * | 2022-11-15 | 2023-01-13 | 中国科学院遗传与发育生物学研究所（Cn） | Application of isochlorogenic acid C in the treatment of myocardial injury caused by antineoplastic drugs |
| CN115590845B (en) * | 2022-11-15 | 2023-10-27 | 中国科学院遗传与发育生物学研究所 | Application of isochlorogenic acid C in the treatment of myocardial injury caused by anti-tumor drugs |
| CN116693585A (en) * | 2023-06-08 | 2023-09-05 | 大洲新燕(厦门)生物科技有限公司 | Method for preparing quercetin-7-O-beta-D-glucoside from dried orange peel and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899297A (en) | Schefflera venulosa extract and use in producing medicine | |
| CN1462620A (en) | Powder of flenabane and its preparation method as well as application in making drugs | |
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN1911257A (en) | Extractive of ginkgo tree leaves, prepn. method and application thereof | |
| CN1771977A (en) | A kind of notoginsengdiol saponin composition and its preparation method and application | |
| CN103271978A (en) | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness | |
| CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN1298705A (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN101744997B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN101073598A (en) | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN101744989B (en) | Method for extracting schisandra chinensis, ginseng and dwarf lilyturf root and preparation thereof | |
| CN1785202B (en) | Medicinal composition for treating cardiovascular disease and its preparation method | |
| CN108059646B (en) | The preparation method of hypoglycemic activity ingredient in a kind of radix rehmanniae recen | |
| CN1785283B (en) | Medicinal composition for treating cardiorascular disease and its preparation method | |
| CN1891249A (en) | Chinese medicine preparation for treating cardio-cerebrovascular disease and its preparing method | |
| CN1634246A (en) | Compound formulation of breviscapine and asarum herb for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1857471A (en) | Tribuloside composition preparing and its preparing process | |
| CN1931248A (en) | Medicine composition and its prepn process | |
| CN1939390A (en) | Medicinal composition and its making method | |
| CN1915273A (en) | Medicinal composition, preparation method and quality control method | |
| CN1915256A (en) | Medicinal composition, preparation method and quality control method | |
| CN102670785A (en) | Preparation method of conventional Chinese medicine composition for treating primary hypertension | |
| CN1759854A (en) | Chinese materia medica preparation for treating cardiovascular and cerebrovascular diseases, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |